Up until now, most research on Methicillin-resistant Staphylococcus aureus (MRSA) has focused on attributes like the amount of toxins or virulence factors that different strains make. A team of scientists at the University of North Carolina School of Medicine in Chapel Hill is taking a different approach.
U.S. researchers have discovered antibacterial compounds that are effective in preclinical studies against MRSA infections, and that could even reverse resistance, making the bacteria vulnerable to antibiotics again.
Redx Pharma, a U.K. biotech based in Liverpool, says it will use a government grant to launch a spinoff to develop new anti-viral and anti-bacterial therapies, with plans to recruit 119 employees for the new project.
Pfizer ($PFE), GlaxoSmithKline ($GSK) and NovaDigm Therapeutics are each in search of a vaccine to put a stop to methicillin-resistant Staphylococcus aureus, known as MRSA, a staph infection that kills more people in the United States than skin cancer, Bloomberg reports.
The lethal spread of MRSA in hospitals and other public places has been driving a number of programs aimed at finding a new vaccine capable of preventing tens of thousands of deaths each year.
The company said its Cubicin antibiotic, targeted at difficult-to-treat skin and bloodstream infections, will account for at least half of those sales.
NovaDigm Therapeutics is developing a vaccine that could work against both bacteria and fungi, and could even combat resistant bacteria such as MRSA. The company presented Phase I results at the 15th Annual Conference on Vaccine Research.
Some researchers recently crunched the numbers of federal drug research support and concluded that despite all the alarms over drug-resistant superbugs each MRSA death translated into only $570 in
Tried as they might, researchers from the Johns Hopkins Bloomberg School of Public Health did not succeed in taking the joy out commencement season. Aside from an annual dusting off of Bartlett's
While Big Pharma still has a strong foothold in the antibiotics market, smaller biotechs have tackled the job of replenishing our arsenal of new weapons against infections--especially so-called